DEFINIENS

Definiens & Targos Innovation: AI-powered multiplex IHC biomarker analytic solutions for precision medicine

Retrieved on: 
Thursday, June 20, 2019
Medicine, Clinical medicine, Health, Biomarkers, Definition, Clinical trial

Definiens and Targos have already collaborated successfully in biomarker services for pharma and academic partners.

Key Points: 
  • Definiens and Targos have already collaborated successfully in biomarker services for pharma and academic partners.
  • On its own, Definiens has provided 2,500+ custom solutions across several indications, while Targos has supported more than 400 global clinical trials.
  • Through this partnership, customers can take advantage of co-validated custom and standardized multiplex IHC solutions.
  • The targeted biomarker spatial and advanced analytics are provided through an interactive online shareable web portal with live status updates.

Definiens & Targos Innovation: AI-powered multiplex IHC biomarker analytic solutions for precision medicine

Retrieved on: 
Thursday, June 20, 2019
Medicine, Clinical medicine, Health, Biomarkers, Definition, Clinical trial

Definiens and Targos have already collaborated successfully in biomarker services for pharma and academic partners.

Key Points: 
  • Definiens and Targos have already collaborated successfully in biomarker services for pharma and academic partners.
  • On its own, Definiens has provided 2,500+ custom solutions across several indications, while Targos has supported more than 400 global clinical trials.
  • Through this partnership, customers can take advantage of co-validated custom and standardized multiplex IHC solutions.
  • The targeted biomarker spatial and advanced analytics are provided through an interactive online shareable web portal with live status updates.

Definiens Launches Immuno-oncology Research Collaboration for AACR 2019 Atlanta

Retrieved on: 
Tuesday, March 26, 2019
Biology, American Association for Cancer Research, Biomarker, Phenomics, Life sciences

MUNICH, March 26, 2019 /PRNewswire/ --Definiens, a leading international artificial intelligence (AI)-based biomarker analysis provider for immuno-oncology therapy research and diagnostics development, launched a special research collaborationinitiative using its IO-Panel this week before AACR Annual Meeting 2019 in Atlanta, Georgia.

Key Points: 
  • MUNICH, March 26, 2019 /PRNewswire/ --Definiens, a leading international artificial intelligence (AI)-based biomarker analysis provider for immuno-oncology therapy research and diagnostics development, launched a special research collaborationinitiative using its IO-Panel this week before AACR Annual Meeting 2019 in Atlanta, Georgia.
  • The Definiens IO-Panel Exploratory Program will accept submissions until April 12 with final partner selection on April 18, 2019.
  • The Definiens IO-Panel Exploratory Program provides both scientific and technological consulting services based on the Tissue Phenomics methodology.
  • Interested parties can also get more information at Definiens Booth #2350 at the American Association of Cancer Research Annual Meeting (AACR 2019) in Atlanta, Georgia between March 31-April 3, 2019.

Definiens to showcase 5 successful immuno-oncology studies at SITC 2018

Retrieved on: 
Tuesday, November 6, 2018
Linguistics, Biotechnology, Logic, Lexicography, Microenvironment, Definition, Biopharmaceutical, Omics

MUNICH, Nov. 6, 2018 /PRNewswire/ --Definiens, the Tissue Phenomics company, today announced that data from five immuno-oncology (IO) studies will be presented at the 2018 SITC Annual Meeting held November 7-10 in Washington, D.C., USA.

Key Points: 
  • MUNICH, Nov. 6, 2018 /PRNewswire/ --Definiens, the Tissue Phenomics company, today announced that data from five immuno-oncology (IO) studies will be presented at the 2018 SITC Annual Meeting held November 7-10 in Washington, D.C., USA.
  • Definiens will be at SITC Booth #310 showcasing the power of integrating Tissue Phenomics with complementary technology to deliver a robust analysis of the tumor microenvironment using a multi-omics approach.
  • Special guest Dr. Bernard Fox of the Earle A. Chiles Research Institute will present his findings of a unique collaborative project between NanoString and Definiens technologies.
  • Additional clients include renowned biopharmaceuticals and prestigious academics, who have collectively published over 1,000 scientific papers using Definiens' products and services.

Definiens showcases pharma solutions for immuno-oncology profiling

Retrieved on: 
Wednesday, October 3, 2018
Medicine, Branches of biology, Biology, Clinical medicine, Biomarkers, Biotechnology, Chemical pathology, Medical signs, Pathology, Phenomics, Digital pathology, Oncology

"This is a very unique opportunity to actively engage with different pharma companies and other experts on their experience in using Tissue Phenomics solutions from Definiens for immuno-oncology, biomarker development and patient profiling,"said Ralf Huss, Chief Medical Officer at Definiens.

Key Points: 
  • "This is a very unique opportunity to actively engage with different pharma companies and other experts on their experience in using Tissue Phenomics solutions from Definiens for immuno-oncology, biomarker development and patient profiling,"said Ralf Huss, Chief Medical Officer at Definiens.
  • Definiens provides IO profiling and digital pathology services that are based largely on the Tissue Phenomics approach.
  • Our mission is to accelerate breakthroughs in immuno-oncology by helping pharmaceutical researchers better leverage tissue-based information through Definiens Tissue Phenomicstechnology.
  • Definiens' proven technology has been used in thousands of projects, yielding results that have accelerated drug development and produced over 1000 peer-reviewed publications.

Definiens showcases pharma solutions for immuno-oncology profiling

Retrieved on: 
Wednesday, October 3, 2018
Medicine, Branches of biology, Biology, Clinical medicine, Biomarkers, Biotechnology, Chemical pathology, Medical signs, Pathology, Phenomics, Digital pathology, Oncology

"This is a very unique opportunity to actively engage with different pharma companies and other experts on their experience in using Tissue Phenomics solutions from Definiens for immuno-oncology, biomarker development and patient profiling,"said Ralf Huss, Chief Medical Officer at Definiens.

Key Points: 
  • "This is a very unique opportunity to actively engage with different pharma companies and other experts on their experience in using Tissue Phenomics solutions from Definiens for immuno-oncology, biomarker development and patient profiling,"said Ralf Huss, Chief Medical Officer at Definiens.
  • Definiens provides IO profiling and digital pathology services that are based largely on the Tissue Phenomics approach.
  • Our mission is to accelerate breakthroughs in immuno-oncology by helping pharmaceutical researchers better leverage tissue-based information through Definiens Tissue Phenomicstechnology.
  • Definiens' proven technology has been used in thousands of projects, yielding results that have accelerated drug development and produced over 1000 peer-reviewed publications.